Cantor Fitzgerald Reaffirms Overweight Rating for Ascendis Pharma A/S (NASDAQ:ASND)

Cantor Fitzgerald restated their overweight rating on shares of Ascendis Pharma A/S (NASDAQ:ASND) in a research note issued to investors on Friday, Benzinga reports. They currently have a $173.00 price objective on the biotechnology company’s stock.

Other research analysts have also recently issued reports about the company. Wedbush raised their target price on Ascendis Pharma A/S from $207.00 to $225.00 and gave the stock an outperform rating in a research report on Thursday, February 8th. Morgan Stanley reaffirmed an equal weight rating and set a $116.00 price objective on shares of Ascendis Pharma A/S in a report on Monday, April 22nd. JPMorgan Chase & Co. upped their target price on shares of Ascendis Pharma A/S from $167.00 to $170.00 and gave the company an overweight rating in a research note on Friday. Wells Fargo & Company raised their price target on shares of Ascendis Pharma A/S from $196.00 to $260.00 and gave the stock an overweight rating in a research note on Friday, March 15th. Finally, Citigroup upped their price objective on Ascendis Pharma A/S from $146.00 to $182.00 and gave the company a buy rating in a research note on Thursday, February 8th. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, Ascendis Pharma A/S currently has a consensus rating of Moderate Buy and a consensus target price of $173.88.

Ascendis Pharma A/S Price Performance

Shares of Ascendis Pharma A/S stock opened at $137.20 on Friday. The company has a market cap of $7.99 billion, a PE ratio of -14.28 and a beta of 0.54. The firm has a fifty day moving average price of $146.67 and a two-hundred day moving average price of $128.07. Ascendis Pharma A/S has a fifty-two week low of $83.75 and a fifty-two week high of $161.00.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings data on Wednesday, February 7th. The biotechnology company reported ($1.66) EPS for the quarter, beating analysts’ consensus estimates of ($2.15) by $0.49. Ascendis Pharma A/S had a negative net margin of 152.68% and a negative return on equity of 16,574.15%. The business had revenue of $148.62 million during the quarter, compared to analyst estimates of $97.02 million. Analysts expect that Ascendis Pharma A/S will post -4.15 earnings per share for the current fiscal year.

Institutional Trading of Ascendis Pharma A/S

Large investors have recently added to or reduced their stakes in the company. GAMMA Investing LLC acquired a new position in shares of Ascendis Pharma A/S in the 4th quarter worth approximately $25,000. Private Ocean LLC bought a new position in Ascendis Pharma A/S in the 1st quarter valued at $36,000. Quadrant Capital Group LLC boosted its stake in Ascendis Pharma A/S by 90.4% in the fourth quarter. Quadrant Capital Group LLC now owns 318 shares of the biotechnology company’s stock worth $40,000 after purchasing an additional 151 shares in the last quarter. EverSource Wealth Advisors LLC grew its holdings in shares of Ascendis Pharma A/S by 37.6% during the fourth quarter. EverSource Wealth Advisors LLC now owns 333 shares of the biotechnology company’s stock worth $42,000 after purchasing an additional 91 shares during the last quarter. Finally, Signaturefd LLC grew its holdings in shares of Ascendis Pharma A/S by 31.9% during the third quarter. Signaturefd LLC now owns 798 shares of the biotechnology company’s stock worth $75,000 after purchasing an additional 193 shares during the last quarter.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.